Ultragenyx Pharmaceutical Inc. Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2013 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Ultragenyx Pharmaceutical Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2013 to Q4 2023.
  • Ultragenyx Pharmaceutical Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $1.04B, a 15.8% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $1.04B +$141M +15.8% Dec 31, 2023 10-K 2024-02-21
Q4 2022 $895M +$194M +27.7% Dec 31, 2022 10-K 2024-02-21
Q4 2021 $701M +$140M +24.9% Dec 31, 2021 10-K 2023-02-17
Q4 2020 $561M +$74.3M +15.3% Dec 31, 2020 10-K 2022-02-15
Q4 2019 $487M +$125M +34.6% Dec 31, 2019 10-K 2021-02-12
Q4 2018 $362M +$57.5M +18.9% Dec 31, 2018 10-K 2020-02-14
Q4 2017 $304M +$91.9M +43.3% Dec 31, 2017 10-K 2019-02-20
Q4 2016 $212M +$103M +94% Dec 31, 2016 10-K 2018-02-21
Q4 2015 $109M +$58.1M +113% Dec 31, 2015 10-K 2017-02-17
Q4 2014 $51.3M +$25.6M +99.8% Dec 31, 2014 10-K 2016-02-26
Q4 2013 $25.7M Dec 31, 2013 10-K 2015-03-27
* An asterisk sign (*) next to the value indicates that the value is likely invalid.